Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.46 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.45 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | KDM5A | P29375 | 3/20 | 0.40 |
| ▸ | CA12 | O43570 | 2/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.39 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19085518 | 0.94 | TSHR (0.56) | TSHRL3MBTL1MEN1KMT2APAOX | |
| SCHEMBL25622494 | 0.92 | L3MBTL1 (0.58) | TSHRL3MBTL1MEN1KMT2APAOX | |
| SCHEMBL10942803 | 0.92 | L3MBTL1 (0.58) | TSHRL3MBTL1MEN1KMT2APAOX | |
| SCHEMBL24263786 | 0.88 | TSHR (0.50) | TSHRL3MBTL1MEN1KMT2APAOX | |
| SCHEMBL25069138 | 0.87 | TSHR (0.48) | TSHRL3MBTL1MEN1KMT2APAOX | |
| SCHEMBL8747893 | 0.86 | KMT2A (0.58) | TSHRL3MBTL1MEN1KMT2APAOX | |
| SCHEMBL12847857 | 0.85 | KMT2A (0.52) | TSHRL3MBTL1MEN1KMT2APAOX | |
| Fluoride SCHEMBL28844140 | 0.84 | KMT2A (0.56) | TSHRL3MBTL1MEN1KMT2APAOX | |
| Hydrochloric Acid SCHEMBL8341262 | 0.83 | TSHR (0.54) | TSHRL3MBTL1MEN1KMT2APAOX | |
| Hydrochloric Acid SCHEMBL8341258 | 0.83 | TSHR (0.68) | TSHRL3MBTL1MEN1KMT2APAOX |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3188760-B1 | LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS | NOVARTIS AG (CH) | 2023-12-06 | — | — | EP | disclosed |
| EP-4223285-A2 | METHOD OF ENCAPSULATING A NUCLEIC ACID IN A LIPID NANOPARTICLE HOST | Novartis AG (CH) | 2023-08-09 | — | — | EP | disclosed |
| EP-3169309-B1 | METHOD OF ENCAPSULATING A NUCLEIC ACID IN A LIPID NANOPARTICLE HOST | NOVARTIS AG (CH) | 2023-05-10 | — | — | EP | disclosed |
| US-20230130822-A1 | LOW TOXICITY NMP SUBSTITUTES AND USES THEREOF | ADVANCION CORPORATION | 2023-04-27 | — | — | US | disclosed |
| US-20230130822-A1 | LOW TOXICITY NMP SUBSTITUTES AND USES THEREOF | ADVANCION CORPORATION | 2023-04-27 | — | — | US | disclosed |
| EP-4019506-A1 | LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS | Novartis AG (CH) | 2022-06-29 | — | — | EP | disclosed |
| EP-3083579-B1 | LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS | NOVARTIS AG (CH) | 2022-01-26 | — | — | EP | disclosed |
| CN-107072946-B | Lipids and lipid compositions for delivery of active agents | 诺华股份有限公司 | 2022-01-11 | — | — | CN | disclosed |
| WO-2021163348-A2 | LOW TOXICITY NMP SUBSTITUTES AND USES THEREOF | ANGUS CHEMICAL COMPANY (US) | 2021-08-19 | — | — | WO | disclosed |
| US-10844002-B2 | Lipids and lipid compositions for the delivery of active agents | NOVARTIS AG (CH) | 2020-11-24 | — | — | US | disclosed |
| US-20170196809-A1 | METHOD OF ENCAPSULATING A NUCLEIC ACID IN A LIPID NANOPARTICLE HOST | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2017-07-13 | — | — | US | disclosed |
| EP-3188760-A1 | LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS | Novartis AG (CH) | 2017-07-12 | — | — | EP | disclosed |
| US-20160139136-A1 | RAPID FLUORESCENCE TAGGING OF GLYCANS AND OTHER BIOMOLECULES WITH ENHANCED MS SIGNALS | WATERS TECHNOLOGIES CORPORATION (US) | 2016-05-19 | — | — | US | disclosed |
| WO-2016037053-A1 | LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS | NOVARTIS AG (CH) | 2016-03-10 | — | — | WO | disclosed |
| WO-2016037053-A1 | LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS | NOVARTIS AG (CH) | 2016-03-10 | — | — | WO | disclosed |
| EP-1095032-B1 | REAGENTS FOR CYP2D FLUORESCENT ASSAY | GENTEST CORP (US) | 2003-12-10 | — | — | EP | disclosed |
| EP-1095032-A1 | NOVEL CYP2D FLUORESCENT ASSAY REAGENTS | GENTEST CORPORATION (US) | 2001-05-02 | — | — | EP | disclosed |
| US-6130342-A | A 2-OXOCHROMAN COMPOUND CONTAINING A QUATERNARY AMINE GROUP | GENTEST CORPORATION (US) | 2000-10-10 | — | — | US | disclosed |
| WO-2000004008-A1 | NOVEL CYP2D FLUORESCENT ASSAY REAGENTS | GENTEST CORPORATION (US) | 2000-01-27 | — | — | WO | disclosed |
| US-5498419-A | SIDE EFFECT REDUCTION | PARS HARRY G (US) | 1996-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10844002-B2 | Lipids and lipid compositions for the delivery of active agents | LRAT, LIPA, LPAR1 | TSHR 584/4885L3MBTL1 3484/4885MEN1 2514/4885 |
| US-20170196809-A1 | METHOD OF ENCAPSULATING A NUCLEIC ACID IN A LIPID NANOPARTICLE HOST | POLN, POLRMT, RNGTT | TSHR 4266/4885L3MBTL1 997/4885MEN1 3053/4885 |
| US-20160139136-A1 | RAPID FLUORESCENCE TAGGING OF GLYCANS AND OTHER BIOMOLECULES WITH ENHANCED MS SIGNALS | FUT5, FUT6, CSGALNACT1 | TSHR 2074/4885L3MBTL1 2584/4885MEN1 2746/4885 |
| US-20230130822-A1 | LOW TOXICITY NMP SUBSTITUTES AND USES THEREOF | NME4, NMBR, NMUR1 | TSHR 3306/4885L3MBTL1 834/4885MEN1 312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.